McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurol. 2002;1(6):343–51.
Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies. Progress in Retinal and Eye Research. 2011;30(2):81–114.
Fraser JA, Biousse V, Newman NJ. The Neuro-ophthalmology of Mitochondrial Disease. Surv Ophthalmol. 2010;55(4):299–334.
Man PY, Griffiths PG, Brown DT, et al. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72(2):333–9.
Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. Journal of Medical Genetics. 2009;46(3):145–58.
•• La Morgia C, Ross-Cisneros FN, Sadun AA, et al.: Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain. 2010;133:2426–38. This paper describes the preservation of a special class of melanopsin-containing RGCs in LHON and DOA, providing for the first time a neuroanatomical basis for the relatively spared pupillary light reflexes in these two disorders.
Chinnery PF, Andrews RM, Turnbull DM, Howell NN. Leber hereditary optic neuropathy: Does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? American Journal of Medical Genetics. 2001;98(3):235–43.
Hudson G, Carelli V, Spruijt L, et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet. 2007;81(2):228–33.
Ji YL, Zhang AM, Jia XY, et al. Mitochondrial DNA Haplogroups M7b1 ′ 2 and M8a Affect Clinical Expression of Leber Hereditary Optic Neuropathy in Chinese Families with the m.11778 G -> A Mutation. Am J Hum Genet. 2008;83(6):760–8.
Bu XD, Rotter JI: X chromosome-linked and mitochondrial gene control of Leber hereditary optic neuropathy: evidence from segregation analysis for dependence on X chromosome inactivation. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(18):8198–202.
Hudson G, Keers S, Man PYW, et al. Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder. Am J Hum Genet. 2005;77(6):1086–91.
Shankar SP, Fingert JH, Carelli V, et al. Evidence for a novel x-linked modifier locus for leber hereditary optic neuropathy. Ophthalmic Genetics. 2008;29(1):17–24.
Ji YL, Jia XY, Li SQ, et al. Evaluation of the X-linked modifier loci for Leber hereditary optic neuropathy with the G11778A mutation in Chinese. Mol Vis. 2010;16(47):416–24.
• Giordano C, Montopoli M, Perli E, et al.: Oestrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy. Brain. 2011;134:220–34. This paper describes an elegant series of experiments showing that estrogens help protect LHON cybrids against the deleterious consequences of the three primary mtDNA mutations. These results support a hormonal component to the reduced disease penetrance observed among female LHON carriers.
Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Progress in Retinal and Eye Research. 2004;23(1):53–89.
• Kirkman MA, Yu-Wai-Man P, Korsten A, et al.: Gene-environment interactions in Leber hereditary optic neuropathy. Brain. 2009;132:2317–26. This is the largest epidemiological study to investigate the role of environmental factors in influencing LHON penetrance. A strong association was identified between the risk of visual loss and smoking. This effect showed a dose–response relationship with heavy smokers being more likely to be affected than light smokers. A trend toward increased visual failure was also noted among LHON carriers with heavy alcohol consumption.
Schapira AHV. Mitochondrial disease. Lancet. 2006;368(9529):70–82.
Gronlund MA, Honarvar AKS, Andersson S, et al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease. Br J Ophthalmol. 2010;94(1):121–7.
Anikster Y, Kleta R, Shaag A, et al. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): Identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet. 2001;69(6):1218–24.
Reynier P, Amati-Bonneau P, Verny C, et al. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. Journal of Medical Genetics. 2004;41(9):e110.
Ryu SW, Jeong HJ, Choi M, et al. Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cellular and Molecular Life Sciences. 2010;67(16):2839–50.
• Yu-Wai-Man P, Griffiths PG, Gorman GS, et al.: Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771–86. This large multicenter study expands the phenotypic spectrum associated with OPA1 mutations. Up to 20% of mutational carriers developed a more severe disease variant (DOA+) characterized by prominent neuromuscular features such as deafness, myopathy, peripheral neuropathy, ataxia, and chronic progressive external ophthalmoplegia. Interestingly, there was a threefold increased risk of developing DOA+ with missense OPA1 mutations involving the GTPase domain compared with other mutational subgroups.
Zuchner S, De Jonghe P, Jordanova A, et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol. 2006;59(2):276–81.
Lenaers G, Reynier P, Elachouri G, et al. OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol. 2009;41(10):1866–74.
Stemmler TL, Lesuisse E, Pain D, Dancis A. Frataxin and Mitochondrial FeS Cluster Biogenesis. J Biol Chem. 2010;285(35):26737–43.
Hanein S, Perrault I, Roche O, et al. TMEM126A, Encoding a Mitochondrial Protein, Is Mutated in Autosomal-Recessive Nonsyndromic Optic Atrophy. Am J Hum Genet. 2009;84(4):493–8.
Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008;131:352–67.
Tang S, Le PK, Tse S, et al. Heterozygous Mutation of Opa1 in Drosophila Shortens Lifespan Mediated through Increased Reactive Oxygen Species Production. PLoS One. 2009;4(2):e4492.
•• de Brito OM, Scorrano L: Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008;456(7222):605–10. This seminal work describes how MFN2 tethers the ER to the mitochondrial network, thereby regulating calcium flux between these two compartments.
de Brito OM, Scorrano L. Mitofusin-2 regulates mitochondrial and endoplasmic reticulum morphology and tethering: The role of Ras. Mitochondrion. 2009;9(3):222–6.
Trevelyan AJ, Kirby DM, Smulders-Srinivasan TK, et al. Mitochondrial DNA mutations affect calcium handling in differentiated neurons. Brain. 2010;133:787–96.
Dayanithi G, Chen-Kuo-Chang M, Viero C, et al. Characterization of Ca2+ signalling in postnatal mouse retinal ganglion cells: involvement of OPA1 in Ca2+ clearance. Ophthalmic Genet. 2010;31(2):53–65.
Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872–84.
Chevrollier A, Guillet V, Loiseau D, et al. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann Neurol. 2008;63(6):794–8.
•• Amati-Bonneau P, Valentino ML, Reynier P, et al.: OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. Brain. 2008;131:338–51. This study established OPA1 as a novel mtDNA maintenance disorder. Skeletal muscle biopsies from these patients revealed high levels of cytochrome c oxidase negative fibers, secondary to the accumulation of clonally expanded mtDNA deletions.
•• Hudson G, Amati-Bonneau P, Blakely EL, et al.: Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain. 2008;131:329–37. This study established OPA1 as a novel mtDNA maintenance disorder. Skeletal muscle biopsies from these patients revealed high levels of cytochrome c oxidase negative fibers, secondary to the accumulation of clonally expanded mtDNA deletions
•• Yu-Wai-Man P, Sitarz KS, Samuels DC, et al.: OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Human Molecular Genetics. 2010;19(15):3043–52. This study established OPA1 as a novel mtDNA maintenance disorder. Skeletal muscle biopsies from these patients revealed high levels of cytochrome c oxidase negative fibers, secondary to the accumulation of clonally expanded mtDNA deletions.
Chen HC, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130(3):548–62.
•• Chen HC, Vermulst M, Wang YE, et al.: Mitochondrial Fusion Is Required for mtDNA Stability in Skeletal Muscle and Tolerance of mtDNA Mutations. Cell. 2010;141(2):280–9. This important study explores the fundamental roles played by mitofusins and OPA1 in both mtDNA maintenance and mitochondrial network stability. Loss of mitochondrial fusion was found to exacerbate mitochondrial dysfunction, with the induction of a compensatory mitochondrial proliferative response, and an increased rate of mtDNA mutagenesis.
•• Elachouri G, Vidoni S, Zanna C, et al.: OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Research. 2011;21(1):12–20. This study provides strong evidence that the peptide segment encoded by exon 4b likely plays a crucial role in physically anchoring nucleoids to the mitochondrial inner membrane.
Yu-Wai-Man P, Bailie M, Atawan A, et al.: Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye. 2011; Epub ahead of print.
Andrews RM, Griffiths PG, Johnson MA, Turnbull DM. Histochemical localisation of mitochondrial enzyme activity in human optic nerve and retina. Br J Ophthalmol. 1999;83(2):231–5.
Bristow EA, Griffiths PG, Andrews RM, et al. The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol. 2002;120(6):791–6.
•• Klopstock K, Yu-Wai-Man P, Dimitriadis K, et al.: A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011; 134(9): 2677–86. This is the first adequately powered treatment trial for LHON, highlighting the benefit of a multinational approach and the need to develop global registries to support patient recruitment for relatively rare genetic diseases. High-dose idebenone is safe and it holds therapeutic potential for affected LHON carriers at highest risk of further visual loss.
Haefeli RH, Erb M, Gemperli AC, Robay D, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One. 2011;6(3):e17963.
Qi XP, Lewin AS, Sun L, et al. SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I. Ann Neurol. 2004;56(2):182–91.
Qi XP, Sun L, Hauswirth WW, et al. Use of mitochondrial antioxidant defenses for rescue of cells with a Leber hereditary optic neuropathy-causing mutation. Arch Ophthalmol. 2007;125(2):268–72.
Ellouze S, Augustin S, Bouaita A, et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet. 2008;83(3):373–87.
Brown DT, Herbert M, Lamb VK, et al. Transmission of mitochondrial DNA disorders: possibilities for the future. Lancet. 2006;368(9529):87–9.
Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63(1):35–9.